Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals (Nasdaq: ANIP) will release its third quarter 2025 financial results on Friday, November 7, 2025 prior to market open.
A conference call with Nikhil Lalwani (CEO), Stephen P. Carey (CFO) and Chris Mutz (Head of Rare Disease) will be held on November 7, 2025 at 8:30 a.m. ET. Investors can join by dialing the U.S. toll-free number 800-267-6316 using conference ID 5120265 or via live webcast at www.anipharmaceuticals.com under the Investors section.
A replay will be available about two hours after the call and remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that results from the NEW DAY clinical trial of ILUVIEN (fluocinolone acetonide 0.19 mg) for diabetic macular edema will be presented in a late-breaking oral session at the American Academy of Ophthalmology (AAO) 2025 Retina Subspecialty Day on October 17, 2025 at 4:39 pm ET.
The release reiterates that NEW DAY results were previously reported and will be further disseminated at multiple meetings; it also restates ILUVIEN's indication for DME in patients previously treated with corticosteroids who did not have a clinically significant intraocular pressure rise, and summarizes key safety data including intraocular pressure and cataract incidence from the trials.
ANI Pharmaceuticals (NASDAQ:ANIP) has announced its participation in two upcoming investor conferences. CEO Nikhil Lalwani and the executive team will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 9:00 AM ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:50 PM ET.
Investors can access both live and archived webcasts through the company's website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replays will remain available for 90 days.
ANI Pharmaceuticals (NASDAQ:ANIP) reported exceptional Q2 2025 results with record-breaking performance across key metrics. The company achieved total net revenues of $211.4 million, representing 53.1% year-over-year growth. Their Rare Disease segment, led by Cortrophin Gel with $81.6 million in revenue (66% YoY growth), was a major contributor.
The company's Generics business generated $90.3 million in revenue, up 22.1% YoY. ANI delivered record quarterly adjusted EBITDA of $54.1 million, a 62.8% increase, and achieved adjusted non-GAAP diluted EPS of $1.80.
Based on strong performance, ANI raised its 2025 guidance, now expecting total revenues of $818-843 million and adjusted non-GAAP EBITDA of $213-223 million. Rare Disease revenues are projected to represent approximately 50% of total company revenues in 2025.
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its second quarter 2025 financial results announcement for Friday, August 8, 2025, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results.
Key executives participating in the call include CEO Nikhil Lalwani, CFO Stephen P. Carey, Head of Rare Disease Chris Mutz, and Chief Medical Officer Mary Pao, M.D., Ph.D. Investors can access the call via toll-free number 800-343-4136 using conference ID 5034065. A webcast will be available on the company's website under the Investors section.
ANI Pharmaceuticals (NASDAQ:ANIP) announced results from the NEW DAY clinical trial evaluating ILUVIEN® for diabetic macular edema (DME) treatment. The study compared ILUVIEN to aflibercept in treatment-naïve patients.
The trial's primary endpoint of reducing supplemental aflibercept injections was not met in the intent-to-treat population (2.4 vs 2.5 injections, p=0.756). However, a secondary endpoint showed significantly longer time between treatments with ILUVIEN (185.4 vs 132.8 days, p<0.001). A post-hoc analysis of patients without protocol deviations showed significant reduction in supplemental injections for the ILUVIEN group (1.8 vs 2.5, p=0.029).
Safety data showed ILUVIEN was well-tolerated but had higher treatment-related adverse events (41%) compared to aflibercept (3%), mainly related to cataracts and increased intraocular pressure.
ANI Pharmaceuticals (NASDAQ:ANIP) announced its participation in the upcoming Leerink Partners Therapeutics Forum, focusing on I&I and Metabolism. The company's President and CEO, Nikhil Lalwani, will be conducting one-on-one meetings with investors during the event, which takes place on July 8, 2025, in Boston, MA.
ANI Pharmaceuticals (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani will present at the upcoming 2025 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for Wednesday, June 4, 2025, at 2:35 PM ET.
Investors can access the live and archived webcast through ANI Pharmaceuticals' website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replay will be available for 60 days after the event. Interested parties can schedule one-on-one meetings with the company by contacting their Jefferies representative.
ANI Pharmaceuticals (NASDAQ: ANIP) has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's presentation is scheduled for Tuesday, May 20, 2025, at 1:30pm ET. CEO Nikhil Lalwani and CFO Stephen Carey will represent the company at the conference.
Investors can access the presentation through a live webcast on ANI's website under the Investors section. The webcast recording will remain available for 90 days after the event. One-on-one meetings with management can be arranged through meetings@hcwco.com.